TXMD•TherapeuticsMD’s third-quarter license revenue rose 61% year over year, driven by a $365,000 IMVEXXY sales milestone payment from Knight. Net income from continuing operations increased to $501,000 from $50,000 a year earlier.
TherapeuticsMD said third-quarter license revenue rose 61% year over year after receiving a $365,000 milestone payment from Knight for IMVEXXY sales. Net income from continuing operations was $501,000, compared with $50,000 a year earlier, while operating expenses were $1.70 million, mainly due to higher legal and professional fees.
The company expects to recognize additional IMVEXXY sales milestone revenue in the fourth quarter of 2026. It continues to evaluate strategic alternatives, including potential mergers or asset sales.
